and RARS-T so far, it had not been possible to define significant differences in the clinical outcome based on the MPLW515 mutational status. 8 Only molecular screening of a larger number of cases of CMPD also mimicking features of RARS-T for MPLW515 mutations will reveal the frequency in these borderline cases. It further remains to be clarified whether JAK2 and MPL mutations can occur in coincidence in RARS-T as it was occasionally reported in CIMF. 7 The different phenotypes of MPLW515-associated disordersFET, CIMF and RARS-TFemphasize that these disorders are probably the result of a more complex genetic network that remains to be clarified by further analysis of positive and negative regulators of the JAK-STAT pathway.
Fully differentiated myeloid cells are derived from a common myeloid precursor, which resides in the bone marrow. Depending on activities of cytokines and transcription factors, the differentiation of the common myeloid precursor gives rise to granulocyte/macrophage progenitors, megakaryocyte/ erythroid progenitors and mast cell/basophil progenitors. 1 The granulocyte/macrophage progenitors further branch into neutrophilic granulocytes or macrophages, dendritic cells and osteoclasts. 2 The development of dendritic cells is stimulated in the presence of interleukin (IL)-4 and granulocyte/macrophage colony-stimulating factor (GM-CSF).
Interestingly, both GM-CSF and IL-4 are also potent inducers of the recently discovered protein DC-STAMP (dendritic cell specific transmembrane protein). DC-STAMP is a novel 470 amino-acid protein preferentially expressed in myeloid DC, macrophages and osteoclasts. [3] [4] [5] DC-STAMP is a conserved multi-membrane spanning protein, with little or no homology to other known proteins. 3, 4, 6 Although the function of DC-STAMP in DC is unknown, recent data indicate a role for DC-STAMP in macrophage and osteoclast fusion. 5 DC-STAMP mRNA is expressed at very low levels in undifferentiated bone marrow cells and monocytes. Upon differentiation of these cells towards DC or macrophage using IL-4 and GM-CSF, DC-STAMP mRNA levels increase and parallel the increase in the expression of CD11c. 3, 4, 6 In freshly isolated spleen cells, DC-STAMP mRNA expression is predominantly restricted to CD11c pos cells and is hardly detectable in CD11c neg cells, including granulocytes. 6 Thus, the expression of DC-STAMP appears to be limited to cells belonging to the common myeloid precursor-derived branch that comprises macrophages, DC and osteoclasts and it is not expressed in neutrophilic granulocytes belonging to the other branch. This expression pattern plus the induction of DC-STAMP by IL-4, which controls the branching in granulocyte/macrophage progenitors development, suggest that DC-STAMP may play a role in the control of myeloid differentiation. We investigated this hypothesis by overexpressing DC-STAMP in murine bone marrow progenitor cells, which were subsequently cultured in various differentiation-inducing conditions. Bone marrow cells were collected from the femurs and tibiae of C57BL6/N female mice as described before. 7 Before retroviral transduction, they were cultured for 2 days in prestimulation medium (Iscove's modified Dulbecco's medium (Gibco, Invitrogen, Carlsbad, CA, USA), 5% fetal calf serum (Intergen, Norcross, GA, USA), 1% bovine serum albumin, 1 mg/ml cytidine, adenosine, uridine, guanosine, 2 0 -deoxycytidine, 2 0 -deoxyadenosine, 2 0 -deoxyguanosine and thymidine, 15 mM cholesterol, 15 mM linolic acid (all from Sigma, St Louis, MO, USA), 50 mM b-mercaptoethanol, 10 mg/ml bovine insulin, antibiotics and antimycotics (all from Gibco)) with growth factors (50 ng/ml murine stem cell factor (SCF), 50 ng/ml human Flt-3L, 10 ng/ml murine IL-12, 10 ng/ml murine IL-3, 10 ng/ml thrombopoietin (all from Peprotech, Rocky Hill, NJ, USA), and 1 mg/ml anti-transforming growth factor-b antibody (R&D systems, Minneapolis, MN, USA)). Ecotropic retroviruses used to transduce the bone marrow cells were generated by transfection of the Phoenix cells with the retroviral vector pLZRS expressing green fluorescent protein (GFP) or DC-STAMP-GFP fusion proteins. One day after transduction, up to 50% of cells with high forward and sideward scatter, characteristic of dividing blast cells, expressed GFP or DC-STAMP-GFP. The fluorescent cells were sorted (Elite, Coulter, Hialeah, FL, USA) by flow cytometry, after which more than 90% of the cells were GFP or DC-STAMP-GFP positive, and remained positive up to 5 days during the course of the experiment. The GFP-expressing cells were used in semisolid colony-forming units assays and liquid cultures.
Analysis of the total number of colony-forming units in methylcellulose under different culture conditions was performed. Figure 1a shows that in presence of pokeweed spleen-conditioned medium (PWM-MSCM), DC-STAMP expression dramatically suppressed (up to 10-fold) the number of colonies as compared to GFP-expressing control cells. In the presence of GM-CSF, the GFP-transduced progenitor cells yielded only 50% of the number of colonies compared to cultures containing PWM-MSCM, whereas the number of colonies obtained with the DC-STAMP-expressing progenitors remained relatively constant. Addition of IL-4 to the cultures with GM-CSF further reduced the number of colonies for GFP-transduced progenitors, while it did not affect the number of colonies for DC-STAMP expressing cells (Figure 1a) . No difference in the relative number of dead cells, as determined by trypan blue exclusion, between GFP-and DC-STAMP-GFP-expressing cells was observed, indicating that the decrease in colonies formed by DC-STAMP-GFP-expressing cells was probably not due to decreased cell viability (data not shown). In all conditions, the expression of DC-STAMP resulted in a decreased size of the more Letters to the Editor compact, granulocyte-type of colonies, whereas the size of the more dispersed macrophage-type colonies was not affected (Figure 1b) .
To further study the effect of DC-STAMP on myeloid development, the colonies obtained in semisolid conditions were harvested, washed and phenotyped by flow cytometry (Figure 1c Letters to the Editor the well, and granulocyte-like colonies containing small round cells forming a compact colony (Figure 3a) . Phenotypical analysis of individual colonies confirmed that cells in the macrophage-type colonies expressed low levels of GR-1, high levels of CD11b and were CD11c positive, while the cells in the granulocyte-type colonies expressed high levels of GR-1, low levels of CD11b and were CD11c negative. No significant differences in the relative numbers of these two types of colonies were observed (Figure 3b ). Further analysis indicated that the granulocyte-like colonies formed by DC-STAMP-expressing cells were significantly smaller than those formed by the GFPexpressing cells. Ninety percent of the granulocyte-like colonies formed by GFP-expressing cells contained over 100 cells (Figure 3c) , with most colonies being 1000 cells or more. In contrast, the granulocyte-like colonies formed by DC-STAMPexpressing cells were rather small and only 30% of these colonies contained more than 100 cells (Figure 3c) , with most colonies containing less than 1000 cells. In line with the semisolid assay, the sizes of the macrophage-like colonies did not differ between the GFP and DC-STAMP-expressing cells. In both cases, circa 50% of the macrophage-like colonies contained 50 cells or more. The fact that especially the size of the granulocyte-like colonies, rather than their number, is affected by DC-STAMP suggests that DC-STAMP selectively inhibits granulocyte development at the level of inhibiting cell proliferation but not survival.
The results presented here show that the expression of DC-STAMP affects myeloid development of hematopoietic progenitor cells, specifically suppressing granulocytic development. The mechanism(s) by which DC-STAMP selectively suppresses the development of neutrophilic granulocytes or their precursors is unknown. Some of the effects of DC-STAMP resembles those of IL-4 and it is therefore interesting to note that IL-4 suppresses colony formation during the early stage, but not the later stage of myeloid development. 8 Indeed, IL-4 has been reported to upregulate DC-STAMP expression upon DC differentiation. 3, 4 Future studies should provide detailed insight in the role of DC-STAMP in the myeloid/granulocyte differentiation pathways. Recently, two powerful prognostic models were described in myeloma. The Intergroupe Francophone du Mye'lome (IFM) model uses genetic factors t(4;14) and/or 17p13 deletion by fluorescent in situ hybridization combined with b-2 microglobulin. The high-risk group in this model, defined by the presence of either t(4;14) or 17p13 depletion and b-2 microglobulin greater than 4 mg l À1 , could dissect the survival of patients in each International Staging Study stage. 1 As the International Staging Study did not fully consider genetic factors, this study in a large cohort of patients definitively validates the importance of genetic factors in multiple myeloma prognosis. The other model from the University of Arkansas School of Medical Sciences (UAMS) is based on the expression of 17 genes (17-gene model). The high-risk index based on this model is an extremely powerful prognostic factor with a hazard ratio in excess of 4.
2 It can also further dissect patients with t(4;14) into two groups with significantly different survival. In this study, first we wanted to validate the prognostic significance of the 17-gene high-risk index in other independent (non-UAMS) data sets, and second examine the relationship between high-risk genetic features and the 17-gene high-risk molecular signature.
For the first objective, we analyzed a Mayo Clinic gene expression profile data set comprising 71 newly diagnosed multiple myeloma patients treated with high-dose melphalan and stem cell transplant (previously published and available in Gene Expression Omnibus, accession number GSE 6477), 3 and for the second objective we analyzed the UAMS data set of 351 newly diagnosed patients treated with total therapy II from the UAMS (Gene Expression Omnibus accession GSE 2658). 4 Both data sets were performed on Affymetrix platform. In the Mayo data set, gene expression profile was performed on malignant plasma cells enriched by positive immunomagnetic selection using CD138 (AutoMACS; Miltenyi-Biotec, Auburn, CA, USA). Bone marrow samples were obtained after informed consent according to the Declaration of Helsinki Principles. The study was approved by the Mayo Clinic Institutional Review Board. CD138 selection was also used to enrich for malignant plasma cells in the UAMS data set. Gene expression intensity values were generated using the Affymetrix MAS 5.0 software, median-centered and analyzed using GeneSpring GX 7.3.1 (Agilent Technologies, Palo Alto, CA, USA). The 17-gene high-risk score is calculated based on published methods.
2 A gene expression profile based proliferation index (PI) was calculated as the median expression of the following genes: CCNB1, MKI67, L5, KIAA0186, CKS1B, TOP2A, UBE2C, ZWINT, 16E1BP, TRIP5, CCNA, p55CDC.
5 Spiked expression of FGFR3 or WHSC1 defines cases with t(4;14). 5 Low TP53 expression was used as a surrogate for 17p13 deletion, as a recent study showed that there is a close association between the cases with lowest TP53 expression and 17p13 deletion. 6 The associations between prognostic factors were assessed using Fisher's exact test. The distribution for overall survival was estimated using the method of Kaplan and Meier. The log-rank test was used to test for differences in survival between groups. Overall survival was calculated
